Afuco™ Anti-FGF23 ADCC Therapeutic Antibody (Burosumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to FGF23. Burosumab is a human monoclonal antibody that can be potentially used in the treatment of Dermatological genetic disorders, Hypophosphatemia, Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS), X-linked (Hereditary hypophosphatemic rickets), Osteomalacia, oncogenic.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-010ML |
| Pricing | Inquiry |
| Host | Human |
| Target | FGF23 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IHC, FC, IP, IF, Inhib |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |